Thyroid cancer follow-up: a personalised plan after treatment

Why thyroid cancer follow-up is not one fixed timetable, what the blood tests and scans are looking for, and how the plan changes as the years pass

Clinical review: September 2026

Finishing thyroid cancer treatment can produce an oddly mixed feeling: relief that the most intensive phase is over, followed by the question nobody can answer with a single date—“So, how will we know that everything is still all right?”

Follow-up is the bridge between those two thoughts. It is not designed to keep you permanently inside the cancer system. It is designed to use the right amount of monitoring for the type of thyroid cancer, the treatment you had and the evidence gathered along the way.

First, the treatment you had changes the tests that make sense

Most follow-up discussion concerns differentiated thyroid cancers, usually papillary or follicular thyroid cancer. Their follow-up is different from that for medullary or anaplastic thyroid cancer, which requires a specialist plan of its own.

Within differentiated thyroid cancer, there is an important practical distinction between having one thyroid lobe removed (a hemithyroidectomy) and having the whole gland removed, sometimes followed by radioactive iodine (RAI). If part of the thyroid remains, it continues to make thyroid protein and hormone. If the thyroid has been removed and RAI used, a blood marker called thyroglobulin becomes more informative.

This is why two people who both say “I had thyroid cancer” may have genuinely different follow-up schedules. It is not a sign that one plan is more careful than another; it is a sign that the biology and treatment history are different.

The three threads of follow-up

1. How you are feeling and what has changed

Appointments should make room for more than recurrence. Voice change, swallowing, neck discomfort, fatigue, mood, fear of recurrence, calcium symptoms after surgery and the practical work of taking levothyroxine all matter.

NICE specifically advises that psychological wellbeing may justify further appointments even when no extra physical test is needed.

New neck swelling, persistent change in voice, difficulty swallowing or other concerning symptoms deserve contact with the thyroid team or GP. They do not automatically mean that cancer has returned, but they should not be silently carried until the next routine appointment.

2. Thyroid hormone tests

After total thyroidectomy, lifelong thyroid-hormone replacement is usually needed. Blood tests help ensure that levothyroxine is replacing the missing hormone safely and that the TSH target matches your current cancer-risk plan.

Sometimes TSH is deliberately kept lower than usual for a period because TSH can stimulate thyroid cells. This is called TSH suppression. It has potential benefits in selected people, but it is not a universal badge of thoroughness: too much thyroid hormone can affect the heart, bones and quality of life. The target should therefore be reviewed as the response to treatment becomes clearer.

3. Thyroglobulin and neck ultrasound, when they will answer a useful question

Thyroglobulin is a protein made by thyroid cells. After total or completion thyroidectomy and RAI, a rising level can be a useful signal that prompts further assessment. It is measured alongside thyroglobulin antibodies, because antibodies can interfere with the result. One number is rarely the whole story; the direction of change and the treatment context are often more helpful.

Thyroglobulin is not routinely useful after a lobectomy because normal remaining thyroid tissue makes it. That is not a missing test; it is a test being used only where it can be interpreted sensibly.

Neck ultrasound looks at the thyroid bed, any remaining thyroid lobe and the neck lymph nodes. It is used according to the risk of recurrence and the clinical question, not as a compulsory annual ritual for every person forever.

Risk changes with the response to treatment

Cancer follow-up is increasingly dynamic. The initial pathology tells the team about the disease at diagnosis. Later results tell the team how the disease has behaved after treatment. A reassuring ultrasound and very low or undetectable thyroglobulin after total thyroidectomy/RAI can allow monitoring to become less intensive. A rising marker, concerning imaging or known persistent disease calls for a different level of attention.

For people treated with total thyroidectomy and RAI, NICE recommends risk-stratified follow-up: lower-risk patients may need at least annual thyroglobulin-based follow-up for a limited period, while higher-risk or persistent disease needs longer, sometimes lifelong, monitoring. For some very small solitary cancers removed completely, routine follow-up may not be needed. That is thoughtful de-escalation, not abandonment.

The evidence for exact duration and frequency is not perfect; guidance therefore combines the available evidence with specialist consensus. Your plan should be revisited rather than copied forward unchanged.

The appointment is also a handover of confidence

Some services use personalised or patient-initiated follow-up. This does not mean you are left to police your own cancer care. It should mean that you have a clear treatment summary, a named route back to the team, planned tests where appropriate and permission to make contact when something changes.

Before being discharged to a less intensive plan, it is reasonable to know:

What type and stage of thyroid cancer did I have?
What operation and additional treatment did I have?
What is my current TSH target, and when will it be reviewed?
Is thyroglobulin useful in my case, and are antibodies affecting its interpretation?
Which symptoms should prompt a call, and who should I contact?
What is the next planned test, and what result would change the plan?

The balanced conclusion

Good follow-up has two jobs: to detect meaningful recurrence early enough to help, and to let life become larger than surveillance when the evidence is reassuring. The safest plan is not necessarily the busiest one. It is the one that understands what your treatment has made measurable, responds to change, and keeps a clear route back to expert care.

Important safety note

Contact your thyroid cancer team or GP promptly about a new neck lump or swelling, persistent worsening hoarseness, new difficulty swallowing, or symptoms that concern you. Seek urgent help for severe breathing difficulty. Do not alter levothyroxine or a TSH-suppression plan without the clinician managing your follow-up.